HealthEquity reported a 20% increase in revenue to $216.1 million, a reduced net loss of $1.6 million, and a 20% increase in Adjusted EBITDA to $73.4 million. The company also saw growth in HSAs, total HSA assets, and total accounts.
Revenue increased by 20% to $216.1 million compared to Q3 FY22.
Net loss decreased to $1.6 million, compared to $5.0 million in Q3 FY22.
Adjusted EBITDA increased by 20% to $73.4 million compared to Q3 FY22.
Total HSAs grew by 23% to 7.7 million compared to Q3 FY22.
For the fiscal year ending January 31, 2023, management expects revenue of $850 million to $860 million, a net loss between $34 million and $27 million, non-GAAP net income between $106 million and $114 million, and Adjusted EBITDA of $261 million to $271 million. For the fiscal year ending January 31, 2024, management expects revenue of approximately $950 million to $970 million and Adjusted EBITDA of approximately 33-34% of revenue.
Visualization of income flow from segment revenue to net income